Source - LSE Regulatory
RNS Number : 2417B
Cizzle Biotechnology Holdings PLC
30 September 2022
 

 

30 September 2022

 

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology", "Cizzle" or the "Company")

 

Total Voting Rights

Cizzle Biotechnology, the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As of 30 September 2022, the Company's issued ordinary share capital consists of 314,114,453 ordinary shares of 0.01 pence each, each with one voting right.  The Company holds no ordinary shares in Treasury.  Therefore, the Company's total number of ordinary shares and voting rights is 314,114,453 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

Cizzle Biotechnology Holdings plc

Via IFC Advisory

Allan Syms (Executive Chairman)


 

Allenby Capital Limited

+44(0) 20 33285656

John Depasquale


Alex Brearley


 

Novum Securities Limited

+44(0) 20 7399 9400

Colin Rowbury

Jon Bellis


 

IFC Advisory Limited

+44(0) 20 3934 6630

Tim Metcalfe

cizzle@investor-focus.co.uk

Florence Chandler


 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAKNNALEAEFA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Cizzle Biotechnology Holdings PLC (CIZ)

0p (0.00%)
delayed 16:57PM